Publications
-
Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin.
Weinberg OK,
Ma L, Seo K, Beck AH, Pai RK, Morales A, Kim Y, Sundram U, Tan D, Horning SJ, Hoppe RT, Natkunam Y, Arber DA.
Am J Surg Pathol.
2009;
33
(4):
591-8
-
Interim positron emission tomography (PET) scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.
Horning SJ,
Juweid ME, Schoder H, Wiseman G, McMillan A, Swinnen LJ, Advani R, Gascoyne R, Quon A.
Blood.
2009
-
Cancer research and privacy: the problem with being joined at the hip.
Horning SJ,
J Clin Oncol.
2009;
27
(24):
3879-80
-
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.
Hochster H,
Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ.
J Clin Oncol.
2009;
27
(10):
1607-14
-
(18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan?
Iagaru A,
Wang Y, Mari C, Quon A, Goris ML, Horning S, Gambhir SS.
Hell J Nucl Med.
2008 Sep-Dec;
11
(3):
153-6
-
Follow-up of adult cancer survivors: new paradigms for survivorship care planning.
Horning SJ,
Hematol Oncol Clin North Am.
2008;
22
(2):
201-10, v
-
Follicular lymphoma, survival, and rituximab: is it time to declare victory?
Horning SJ,
J Clin Oncol.
2008;
26
(28):
4537-8
-
Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
Chen AI,
McMillan A, Negrin RS, Horning SJ, Laport GG.
Biol Blood Marrow Transplant.
2008;
14
(7):
741-7
-
Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease.
Advani R,
Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ.
J Clin Oncol.
2007;
25
(25):
3902-7
-
Non-Hodgkin lymphoma of the breast.
Ganjoo K,
Advani R, Mariappan MR, McMillan A, Horning S.
Cancer.
2007;
110
(1):
25-30
-
Revised response criteria for malignant lymphoma.
Cheson BD,
Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V.
J Clin Oncol.
2007;
25
(5):
579-86
-
Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease.
Heidenreich PA,
Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, Tate DJ, Horning SJ, Hoppe RT, Hancock SL.
J Clin Oncol.
2007;
25
(1):
43-9
-
Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine.
Advani R,
Horwitz S, Zelenetz A, Horning SJ.
Leuk Lymphoma.
2007;
48
(3):
521-5
-
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Law LY,
Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.
Biol Blood Marrow Transplant.
2006;
12
(7):
703-11
-
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Habermann TM,
Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ.
J Clin Oncol.
2006;
24
(19):
3121-7
-
Management of advanced stage Hodgkin lymphoma.
Advani R,
Ai WZ, Horning SJ.
J Natl Compr Canc Netw.
2006;
4
(3):
241-7
-
Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis.
Ganjoo KN,
An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, Li S, Weller EA, Orazi A, Horning SJ.
Leuk Lymphoma.
2006;
47
(6):
998-1005
-
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
Horning SJ,
Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M.
J Clin Oncol.
2005;
23
(4):
712-9
-
Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
Meyer RM,
Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR, Djurfeldt MS, Ding K, Shepherd LE.
J Clin Oncol.
2005;
23
(21):
4634-42
-
Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients.
Beynet DP,
Wee SA, Horwitz SS, Kohler S, Horning S, Hoppe R, Kim YH.
Arch Dermatol.
2004;
140
(9):
1140-6
-
Rituximab in stem cell transplantation for aggressive lymphoma.
Horwitz SM,
Horning SJ.
Curr Hematol Rep.
2004;
3
(4):
227-9
-
Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.
Horning SJ,
Weller E, Kim K, Earle JD, O'Connell MJ, Habermann TM, Glick JH.
J Clin Oncol.
2004;
22
(15):
3032-8
-
Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy.
Advani R,
Rosenberg SA, Horning SJ.
J Clin Oncol.
2004;
22
(8):
1454-9
-
Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.
Horwitz SM,
Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE, Johnston LJ, Wong RM, Shizuru JA, Horning SJ.
Blood.
2004;
103
(3):
777-83
-
Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.
Ekstrand BC,
Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT, Natkunam Y, Bartlett NL, Horning SJ.
Blood.
2003;
101
(11):
4285-9
-
Future directions in radioimmunotherapy for B-cell lymphoma.
Horning SJ,
Semin Oncol.
2003;
30
(6 Suppl 17):
29-34
-
Lymphocyte predominant Hodgkin's disease: more patience than patients.
Ekstrand BC,
Horning SJ.
Cancer J.
2002 Sep-Oct;
8
(5):
367-8
-
Lymphocyte predominant Hodgkin's disease.
Ekstrand BC,
Horning SJ.
Curr Oncol Rep.
2002;
4
(5):
424-33
-
Hodgkin's disease.
Ekstrand BC,
Horning SJ.
Blood Rev.
2002;
16
(2):
111-7
-
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial.
Horning SJ,
Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA.
J Clin Oncol.
2002;
20
(3):
630-7
-
Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.
Stuart MJ,
Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ, Shizuru JA, Long GD, Blume KG, Stockerl-Goldstein KE.
Biol Blood Marrow Transplant.
2001;
7
(10):
552-60
-
Durable remission in recurrent T-cell-rich B-cell lymphoma with the anti-CD20 antibody rituximab.
Natkunam Y,
Stanton TS, Warnke RA, Horning SJ.
Clin Lymphoma.
2001;
2
(3):
185-7
-
High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience.
Cao TM,
Horning S, Negrin RS, Hu WW, Johnston LJ, Taylor TL, Shizuru JA, Hoppe RT, Brown BW, Blume KG, Stockerl-Goldstein KE.
Biol Blood Marrow Transplant.
2001;
7
(5):
294-301
-
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial.
Horning SJ,
Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, Long GD, Brown BW, Blume KG.
Blood.
2001;
97
(2):
404-9
-
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Johnston LJ,
Stockerl-Goldstein KE, Hu WW, Negrin RS, Hoppe RT, Blume KG, Horning SJ.
Biol Blood Marrow Transplant.
2000;
6
(5A):
555-62
-
Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells.
Stockerl-Goldstein KE,
Reddy SA, Horning SF, Blume KG, Chao NF, Hu WW, Johnston LF, Long GD, Strober S, Wong RM, Feiner RH, Kobler S, Negrin RS.
Biol Blood Marrow Transplant.
2000;
6
(5):
506-12
-
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
Alvarnas JC,
Negrin RS, Horning SJ, Hu WW, Long GD, Schriber JR, Stockerl-Goldstein K, Tierney K, Wong R, Blume KG, Chao NJ.
Biol Blood Marrow Transplant.
2000;
6
(3A):
352-8
-
Autologous hematopoietic cell transplantation in Hodgkin's disease.
Johnston LJ,
Horning SJ.
Biol Blood Marrow Transplant.
2000;
6
(3A):
289-300
-
Advances in the treatment of Hodgkin's lymphoma.
Horwitz SM,
Horning SJ.
Curr Opin Hematol.
2000;
7
(4):
235-40
-
Follicular lymphoma: have we made any progress?
Horning SJ,
Ann Oncol.
2000:
11 Suppl 1
23-7
-
Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492.
Horning SJ,
Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, Cassileth P.
J Clin Oncol.
2000;
18
(5):
972-80
-
Autologous hematopoietic cell transplantation in non-Hodgkin's lymphoma.
Johnston LJ,
Horning SJ.
Hematol Oncol Clin North Am.
1999;
13
(5):
889-918
-
Treatment of early-stage Hodgkin's disease.
Advani RH,
Horning SJ.
Semin Hematol.
1999;
36
(3):
270-81
-
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.
Cheson BD,
Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP.
J Clin Oncol.
1999;
17
(4):
1244
-
Primary refractory Hodgkin's disease.
Horning SJ,
Ann Oncol.
1998:
9 Suppl 5
S97-101
-
A prognostic score for advanced Hodgkin’s disease.
Hasenclever D,
Diehl V, Armitage JO, Assouline D, Bjorkholm M, Brusamolino E, Cannelos GP, Carde P, Crowther D, Cunningham D, Eghbali H, Ferme C, Fisher RI, Glick JH, Glimelius B, Gobbi PG, Holte H, Horning SJ et al..
New England Journal of Medicine.
1998;
229
(21):
1506–14
-
Advances in the management of Hodgkin's and non-Hodgkin's lymphoma.
Davis TA,
Horning SJ.
Curr Opin Hematol.
1998;
5
(4):
259-63
-
Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease.
Yuen AR,
Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ.
Blood.
1997;
89
(3):
814-22
-
High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices.
Horning SJ,
Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG.
Blood.
1997;
89
(3):
801-13
-
Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine.
Advani R,
Warnke R, Sikic BI, Horning S.
Ann Oncol.
1997;
8
(6):
601-3
-
High-dose therapy and transplantation for low-grade lymphoma.
Horning SJ,
Hematol Oncol Clin North Am.
1997;
11
(5):
919-35
-
Recent advances in the treatment of Hodgkin's disease.
Yuen AR,
Horning SJ.
Curr Opin Hematol.
1997;
4
(4):
286-90
-
Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation.
Horning SJ,
Hoppe RT, Mason J, Brown BW, Hancock SL, Baer D, Rosenberg SA.
J Clin Oncol.
1997;
15
(5):
1736-44
-
Purine analogs in marginal-zone lymphomas.
Horning SJ,
Ann Oncol.
1996:
7 Suppl 6
S21-6
-
Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update.
Horning SJ,
Rosenberg SA, Hoppe RT.
Ann Oncol.
1996:
7 Suppl 4
105-8
-
Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
Stockerl-Goldstein KE,
Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD, Hoppe RT, Amylon MD, Brown BW, Wong RM, Blume KG.
Biol Blood Marrow Transplant.
1996;
2
(2):
76-85
-
A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma.
Chao NJ,
Kastrissios H, Long GD, Negrin RS, Horning SJ, Wong RM, Blaschke TF, Blume KG.
Cancer.
1995;
75
(6):
1354-9
-
Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.
Bartlett NL,
Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ.
J Clin Oncol.
1995;
13
(5):
1080-8
-
Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma.
Negrin RS,
Kusnierz-Glaz CR, Still BJ, Schriber JR, Chao NJ, Long GD, Hoyle C, Hu WW, Horning SJ, Brown BW.
Blood.
1995;
85
(11):
3334-41
-
Long-term survival after histologic transformation of low-grade follicular lymphoma.
Yuen AR,
Kamel OW, Halpern J, Horning SJ.
J Clin Oncol.
1995;
13
(7):
1726-33
-
Recent advances in Hodgkin's disease.
Yuen AR,
Horning SJ.
Curr Opin Hematol.
1995;
2
(4):
262-7
-
Treatment approaches to the low-grade lymphomas.
Horning SJ,
Blood.
1994;
83
(4):
881-4
-
Follicular large-cell lymphoma: intermediate or low grade?
Bartlett NL,
Rizeq M, Dorfman RF, Halpern J, Horning SJ.
J Clin Oncol.
1994;
12
(7):
1349-57
-
Low-grade lymphoma 1993: state of the art.
Horning SJ,
Ann Oncol.
1994:
5 Suppl 2
23-7
-
Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study.
Horning SJ,
Adhikari A, Rizk N, Hoppe RT, Olshen RA.
J Clin Oncol.
1994;
12
(2):
297-305
-
Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ,
Negrin RS, Chao JC, Long GD, Hoppe RT, Blume KG.
J Clin Oncol.
1994;
12
(12):
2552-8
-
MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices.
Bartlett NL,
Kwak LW, Horning SJ.
Cancer.
1993;
71
(12):
4034-42
-
Natural history of and therapy for the indolent non-Hodgkin's lymphomas.
Horning SJ,
Semin Oncol.
1993;
20
(5 Suppl 5):
75-88
-
Granulocyte colony-stimulating factor "mobilized" peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy.
Chao NJ,
Schriber JR, Grimes K, Long GD, Negrin RS, Raimondi CM, Horning SJ, Brown SL, Miller L, Blume KG.
Blood.
1993;
81
(8):
2031-5
-
Hodgkin's disease with bulky mediastinal involvement: effective management with combined modality therapy.
Behar RA,
Horning SJ, Hoppe RT.
Int J Radiat Oncol Biol Phys.
1993;
25
(5):
771-6
-
Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma.
Chao NJ,
Berry GJ, Advani R, Horning SJ, Weiss LM, Blume KG.
Transplantation.
1993;
55
(6):
1425-8
-
The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow.
Schriber JR,
Negrin RS, Chao NJ, Long GD, Horning SJ, Blume KG.
Leukemia.
1993;
7
(10):
1491-5
-
Dynamic assessment of quality of life after autologous bone marrow transplantation.
Chao NJ,
Tierney DK, Bloom JR, Long GD, Barr TA, Stallbaum BA, Wong RM, Negrin RS, Horning SJ, Blume KG.
Blood.
1992;
80
(3):
825-30
-
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.
Advani R,
Chao NJ, Horning SJ, Blume KG, Ahn DK, Lamborn KR, Fleming NC, Bonnem EM, Greenberg PL.
Ann Intern Med.
1992;
116
(3):
183-9
-
The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease.
Horning SJ,
Ang PT, Hoppe RT, Rosenberg SA.
Ann Oncol.
1992;
3
(9):
747-54
-
The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
Horning SJ,
Chao NJ, Negrin RS, Hoppe RT, Kwak LW, Long GD, Stallbaum B, O'Connor P, Blume KG.
Ann Oncol.
1991:
2 Suppl 1
47-50
-
The Stanford Hodgkin's disease (HD) studies--an update.
Horning SJ,
Leukemia.
1991:
5 Suppl 1
53-5
-
Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients.
Chao NJ,
Duncan SR, Long GD, Horning SJ, Blume KG.
Ann Intern Med.
1991;
114
(2):
145-6
-
Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience.
Kwak LW,
Wilson M, Weiss LM, Doggett R, Dorfman RF, Warnke RA, Horning SJ.
J Clin Oncol.
1991;
9
(8):
1426-31
-
Molecular biologic studies in the clinical evaluation of non-Hodgkin's lymphoma.
Hardy R,
Horning SJ.
Hematol Oncol Clin North Am.
1991;
5
(5):
891-900
-
Clinical significance of morphologic subdivision in diffuse large cell lymphoma.
Kwak LW,
Wilson M, Weiss LM, Horning SJ, Warnke RA, Dorfman RF.
Cancer.
1991;
68
(9):
1988-93
-
Detection of non-Hodgkin's lymphoma in the peripheral blood by analysis of antigen receptor gene rearrangements: results of a prospective study.
Horning SJ,
Galili N, Cleary M, Sklar J.
Blood.
1990;
75
(5):
1139-45
-
Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.
Kwak LW,
Halpern J, Olshen RA, Horning SJ.
J Clin Oncol.
1990;
8
(6):
963-77
-
Bone marrow transplantation for hematologic malignancies: the Stanford experience.
Chao NJ,
Amylon MD, Long GD, Negrin RS, Hoppe RT, Horning SJ, Blume KG.
Clin Transpl.
1990:
157-63
-
CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma.
Chao NJ,
Rosenberg SA, Horning SJ.
Blood.
1990;
76
(7):
1293-8
-
Numbers of host "helper" T cells and proliferating cells predict survival in diffuse small-cell lymphomas.
Medeiros LJ,
Picker LJ, Gelb AB, Strickler JG, Brain SW, Weiss LM, Horning SJ, Warnke RA.
J Clin Oncol.
1989;
7
(8):
1009-17
-
Non-Hodgkin lymphoma: influence of lymphography, CT, and bone marrow biopsy on staging and management.
Pond GD,
Castellino RA, Horning S, Hoppe RT.
Radiology.
1989;
170
(1 Pt 1):
159-64
-
Expression of LFA-1 in non-Hodgkin's lymphoma.
Medeiros LJ,
Weiss LM, Picker LJ, Clayberger C, Horning SJ, Krensky AM, Warnke RA.
Cancer.
1989;
63
(2):
255-9
-
Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon.
Brown SL,
Miller RA, Horning SJ, Czerwinski D, Hart SM, McElderry R, Basham T, Warnke RA, Merigan TC, Levy R.
Blood.
1989;
73
(3):
651-61
-
Current Stanford clinical trials for Hodgkin's disease.
Hoppe RT,
Horning SJ, Hancock SL, Rosenberg SA.
Recent Results Cancer Res.
1989:
117
182-90
-
Lymphomas presenting as histologically unclassified neoplasms: characteristics and response to treatment.
Horning SJ,
Carrier EK, Rouse RV, Warnke RA, Michie SA.
J Clin Oncol.
1989;
7
(9):
1281-7
-
Small lymphocytic lymphoma.
Morrison WH,
Hoppe RT, Weiss LM, Picozzi VJ, Horning SJ.
J Clin Oncol.
1989;
7
(5):
598-606
-
Transferrin receptor expression by non-Hodgkin's lymphomas. Correlation with morphologic grade and survival.
Medeiros LJ,
Picker LJ, Horning SJ, Warnke RA.
Cancer.
1988;
61
(9):
1844-51
-
Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials.
Hancock SL,
Hoppe RT, Horning SJ, Rosenberg SA.
Ann Intern Med.
1988;
109
(3):
183-9
-
Comparison of "host cell infiltrates" in patients with follicular lymphoma with and without spontaneous regression.
Strickler JG,
Copenhaver CM, Rojas VA, Horning SJ, Warnke RA.
Am J Clin Pathol.
1988;
90
(3):
257-61
-
Combined modality therapy for stage I-II large cell lymphoma.
Prestidge BR,
Horning SJ, Hoppe RT.
Int J Radiat Oncol Biol Phys.
1988;
15
(3):
633-9
-
Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease.
Horning SJ,
Hoppe RT, Hancock SL, Rosenberg SA.
J Clin Oncol.
1988;
6
(12):
1822-31
Navigation for This Section: Stanford Cancer Center
Profile Administration
Help
Trial Administration